Nanoscope in the News
-
Ophthalmology 360: VIDEO: Two-year results of RESTORE study highlight a mutation-agnostic gene therapy for retinitis pigmentosa
October 31, 2024 by Nanoscope Therapeutics
-
Healio/Ocular Surgery News: VIDEO: Nanoscope Therapeutics shares status update
October 28, 2024 by Nanoscope Therapeutics
-
HCP Live: VIDEO: Allen C. Ho, MD: Efficacy, Safety of MCO-010 for Retinitis Pigmentosa at 2 Years
October 24, 2024 by Nanoscope Therapeutics
-
Healio/Ocular Surgery News: VIDEO: Optogenetic therapy trial in retinitis pigmentosa meets safety, efficacy endpoints
October 21, 2024 by Nanoscope Therapeutics
-
Ophthalmology Times: AAO 2024: New gene therapy shows promise for treatment of retinitis pigmentosa
October 20, 2024 by Nanoscope Therapeutics
-
Ocular Surgery News: VIDEO: Optogenetic therapy shows promise for inherited retinal dystrophies
October 1, 2024 by Nanoscope Therapeutics
-
Max-Planck-Gesellschft: Nanoscope Therapeutics licenses optogenetic technology
September 30, 2024 by Nanoscope Therapeutics
-
HCP Live: Nanoscope Reports Positive End-of-Phase 2 Meeting for MCO-010 Gene Therapy
September 13, 2024 by Nanoscope Therapeutics
-
Retina Specialist: ARVO 2024 Highlights – Optogenetic therapy for retinitis pigmentosa yields BCVA improvement at one year
August 21, 2024 by Nanoscope Therapeutics
-
Ocular Surgery News: VIDEO: MCO-010 for retinitis pigmentosa improves vision in phase 2b/3 study
August 11, 2024 by Nanoscope Therapeutics
-
Modern Retina: ASRS 2024: RESTORE trial 100-week results presented by Dr. Michael Singer
July 27, 2024 by Nanoscope Therapeutics
-
Ocular Surgery News: VIDEO: Optogenetic therapy shows vision improvements, safety at 12 months
May 7, 2024 by Nanoscope Therapeutics
-
Longevity Technology: Nanoscope targets FDA approval following positive gene therapy trial results
March 28, 2024 by Nanoscope Therapeutics
-
Pharmaceutical Technology: Nanoscope Therapeutics exhibits positive top-line Phase IIb results for MCO-010
March 28, 2024 by Nanoscope Therapeutics
-
Ocular Surgery News: Gene therapy improves vision in patients with retinitis pigmentosa in phaase 2b trial
March 27, 2024 by Nanoscope Therapeutics
-
Modern Retina: Nanoscope Therapeutics lead candidate MCO-010 meets endpoints in RESTORE trial for retinitis pigmentosa
March 26, 2024 by Nanoscope Therapeutics
-
Pharmaphorum: Nanoscope preps filing for retinitis pigmentosa gene therapy
March 26, 2024 by Nanoscope Therapeutics
-
Fierce Biotech: Nanoscope eyes market after gene therapy restores vision for patients with retinal disease
March 26, 2024 by Nanoscope Therapeutics
-
Modern Retina : https://www.modernretina.com/view/mco-010-optogenetic-gene-therapy-for-severe-vision-loss-in-stargardt-disease
November 20, 2023 by Nanoscope Therapeutics
-
The Healthcare Technology Report: The Top 25 Women Leaders in Biotechnology of 2023
November 20, 2023 by Nanoscope Therapeutics
-
Eyewire.com : Nanoscope Therapeutics Wins ‘Best of Show’ Award at AAO Eyecelerator 2023
November 10, 2023 by Nanoscope Therapeutics
-
Healio : VIDEO: Optogenetic Therapy Shows Promise in Advanced Retinitis Pigmentosa
October 17, 2023 by Nanoscope Therapeutics
-
Modern Retina: Euretina 2024: Safety and efficacy through week 48 in the Phase 2a STARLIGHT clinical trial
October 6, 2023 by Nanoscope Therapeutics
-
Modern Retina : Gene Therapy: What’s to Come?
September 18, 2023 by Nanoscope Therapeutics
-
Retina Today : The Latest in Gene Therapy Clinical Trials for IRD
August 21, 2023 by Nanoscope Therapeutics
-
Ophthalmology Times : ASRS 2023: The STARLIGHT Study
August 6, 2023 by Nanoscope Therapeutics
-
Healio : Video: Early Data on Optogenetic Therapy in Stargardt Disease Promising
August 6, 2023 by Nanoscope Therapeutics
-
Eye on the Cure Podcast Episode #46 : Aaron Osborne, MD, Chief Medical Officer and Chief Development Office of Nanoscope Therapeutics
May 24, 2023 by Nanoscope Therapeutics
-
Clinical Trials Arena : Nanoscope reveals key efficacy data from Phase IIb ophthalmology trial
April 28, 2023 by Nanoscope Therapeutics
-
Ophthalmology Times : Nanoscope Therapeutics presents results from phase 2b RESTORE trial of MCO-010 for treatment of retinitis pigmentosa
April 28, 2023 by Nanoscope Therapeutics
-
Global Genes: Nanoscope Reports Positive Topline Results from Phase 2b Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
April 10, 2023 by Nanoscope Therapeutics
-
Clinical Trials Arena: Nanoscope’s Gene Therapy Nabs Phase II Win in Retinitis Pigmentosa
March 30, 2023 by Nanoscope Therapeutics
-
Fierce Biotech: Nanoscope’s Phase 2Win for Gene Therapy Shows Potential of Light-sensitive Approach to Eye Disease
March 30, 2023 by Nanoscope Therapeutics
-
Dallas Innovates: Nanoscope Therapeutics bolsters board with addition of ophthalmic veteran as strategic adviser
March 22, 2023 by Nanoscope Therapeutics
-
The Future 50 in Dallas-Fort Worth 2023: Meet the Game-Changing Disruptors Driving Innovation and Impace
March 17, 2023 by Nanoscope Therapeutics
-
Modern Retina: Nanoscope Therapeutics announces WHO selection of ‘sonpiretigene isteparvovec’ as international nonproprietary name for MCO-010
March 1, 2023 by Nanoscope Therapeutics
-
CGT Live: 10 Cell and Gene Therapies to Watch in 2023
January 25, 2023 by Nanoscope Therapeutics
-
Modern Retina: FDA grants fast track designation to Nanoscope Therapeutics for MCO-010 for the treatment of retinitis pigmentosa
October 18, 2022 by Nanoscope Therapeutics
-
Ocular Surgery News: Retinitis Pigmentosa Treatment Receives Fast Track Designation
October 18, 2022 by Nanoscope Therapeutics
-
Euretina Congress Daily: Making Headway in the Battle Against Inherited Retinal Disease
September 15, 2022 by Nanoscope Therapeutics
-
Ophthalmology Times: Enrollment Complete in STARLIGHT Phase 2 Clinical Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Disease
September 13, 2022 by Nanoscope Therapeutics
-
Meet the 43 Finalists for the 2022 Tech Titans Awards
September 9, 2022 by Nanoscope Therapeutics
-
CityBiz: TechFW Member Nanoscope Starts Second Stage 2 Trial
July 26, 2022 by Nanoscope Therapeutics
-
CGT Live: Nanoscope Gene Therapy Continues Progress in Stargardt Disease
July 26, 2022 by Nanoscope Therapeutics
-
Ocular Surgery News: Phase 2 gene therapy trial for Stargardt disease underway
July 26, 2022 by Nanoscope Therapeutics
-
Ophthalmology Times: Nanoscope Therapeutics announces first patient dosed in STARLIGHT Phase 2 clinical trial of MCO-010 optogenetic gene therapy for Stargardt disease
July 25, 2022 by Nanoscope Therapeutics
-
Retina Synthesis: Optogenetics Interview with Samarendra Mohanty, PhD and Charles Wykoff, MD
May 3, 2022 by Nanoscope Therapeutics
-
Healio: Gene therapy platform for Stargardt macular degeneration receives IND clearance
January 25, 2022 by Nanoscope Therapeutics
-
Ophthalmology Times: Nanoscope Therapeutics announces FDA clearance of IND for MCO-010 gene therapy in Stargardt patients
January 25, 2022 by Nanoscope Therapeutics
-
Photonics West BIOS Show Daily: Optogenetics a Promising Route to Vision Restoration
January 22, 2022 by Nanoscope Therapeutics
-
Ft Worth Business Press: TechFW Client Nanoscope Receives $1.5M Grant to Move Macular Degeneration Therapy Forward
September 21, 2021 by Nanoscope Therapeutics
-
Dallas Innovates: Nanoscope Awarded $1.5 Million Grant for Eyesight Gene Therapy as it ‘Takes Steps to Go Public’
September 17, 2021 by Nanoscope Therapeutics
-
Journal of Cellular and Molecular Medicine: Biodistribution of adeno-associated virus type 2 carrying multi-characteristic opsin in dogs following intravitreal injection
August 23, 2021 by Nanoscope Therapeutics
-
The Science Advisory Board: Optogenetic gene therapy provides hope for retinitis pigmentosa patients
August 6, 2021 by Nanoscope Therapeutics
-
Fort Worth Business Press: First patient receives innovative gene therapy eye treatment from TechFW client
August 4, 2021 by Nanoscope Therapeutics
-
Retina Today: AAV Gene Therapy Trials to Watch
August 3, 2021 by Nanoscope Therapeutics
-
BIO.org: The Pandemic Highlights Need for More Women Scientists
July 28, 2021 by Nanoscope Therapeutics
-
Modern Retina: Optogenetic Gene Trial Begins, First Patient Dosed
July 28, 2021 by Nanoscope Therapeutics
-
Ophthalmology Times: First patient dosed in optogenetic gene therapy trial
July 19, 2021 by Nanoscope Therapeutics
-
Fighting Blindness Foundation: Nanoscope Therapeutics Launches Phase 2b Clinical Trial for Optogenetic Therapy
July 19, 2021 by Nanoscope Therapeutics
-
Fort Worth Inc.: Bedford’s Nanoscope Begins Human Trial of Drug for Retinitis Pigmentosa
July 19, 2021 by Nanoscope Therapeutics
-
BioSpace: Nanoscope Therapeutics Announces FDA Approval of IND for Phase 2b Clinical Trial of Optogenetic Gene Monotherapy to Restore Vision in Patients with RP
June 24, 2021 by Nanoscope Therapeutics
-
Ft. Worth Business Press: Nanoscope Therapeutics cleared to open Phase 2b clinical trial for vision therapy
June 23, 2021 by Nanoscope Therapeutics
-
Dallas Morning News: Bedford biotech’s eyesight-restoring gene therapy received FDA approval to test in the U.S.
June 23, 2021 by Nanoscope Therapeutics
-
Dallas Innovates: Bedford Biotech Restores “Meaningful Vision” in Blind Patients With Gene Therapy—and May Soon Go Public
June 22, 2021 by Nanoscope Therapeutics
-
Forbes: What is ‘Optogenetics’? Behind the Technology That’s Bringing Sight to The Blind.
June 16, 2021 by Nanoscope Therapeutics
-
Fort Worth Business: North Texas biotechnology company shows vision improvement via gene therapy
June 4, 2021 by Nanoscope Therapeutics
-
Dallas Morning News: Bedford Biotech’s Gene Therapy Improves Sight for 11 Patients with Rare Genetic Retinal Disorder
June 4, 2021 by Nanoscope Therapeutics
-
Citybiz: Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosa
June 3, 2021 by Nanoscope Therapeutics
-
Opthalmology Times: Optogenetic gene therapy restores vision in 11 RP patients
June 3, 2021 by Nanoscope Therapeutics
-
Ocular Surgery News: Optogenetics, goggles increase visual perception in case of inherited retinal dystrophy
June 3, 2021 by Nanoscope Therapeutics
-
Nature Gene Therapy: Sensitization of ON-bipolar cells with ambient light activatable multi-characteristic opsin rescues vision in mice
May 19, 2021 by Nanoscope Therapeutics
-
14 Emerging Tech Trends for 2021—and Dallas-Area Companies That Are Innovating for the Future
March 6, 2021 by Nanoscope Therapeutics
-
Nature: Light-activated genetic therapy to treat blindness enters clinic
February 9, 2021 by Nanoscope Therapeutics
-
Injection that could improve fading sight in aging eyes starts human trials after curing blindness in mice
October 22, 2020 by Nanoscope Therapeutics
-
Human trials for genetic jab that lets blind mice see again
October 22, 2020 by Nanoscope Therapeutics
-
Nanoscope Therapeutics Closes Series A, Names Alvaro Guillem as Chairman
July 21, 2020 by Nanoscope Therapeutics
-
Two TechFW Clients Receive Awards from NASA and the National Eye Institute
June 1, 2020 by Nanoscope Therapeutics
-
Dallas Morning News: Bedford biomedical firm wins major backing for tech that could restore damaged retinas
September 24, 2018 by Nanoscope Therapeutics